Suggested remit: To appraise the clinical and cost effectiveness of mobocertinib within its marketing authorisation for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 3984

Email enquiries


Key events during the development of the guidance:

Date Update
10 September 2021 - 08 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 May 2021 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance